<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467933</url>
  </required_header>
  <id_info>
    <org_study_id>JPAL-LETTERS-SEROQUEL</org_study_id>
    <nct_id>NCT02467933</nct_id>
  </id_info>
  <brief_title>The Effect of Informative Letters on the Prescription and Receipt of Seroquel</brief_title>
  <official_title>The Effect of Informative Letters on the Prescription and Receipt of Seroquel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abdul Latif Jameel Poverty Action Lab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Medicare and Medicaid Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Services Administration (GSA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Abdul Latif Jameel Poverty Action Lab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abusive prescribing exposes patients to unnecessary health risks and results in wasteful&#xD;
      public expenditures. This study will evaluate an innovative approach to fighting abusive&#xD;
      prescription: sending letters to suspected inappropriate prescribers warning them that they&#xD;
      are outliers compared to their peers and have been flagged for review. The study will target&#xD;
      high prescribers of Seroquel (Quetiapine), an atypical antipsychotic. Using claims data, the&#xD;
      investigators will assess the effect of the letters on prescribing of Seroquel, receipt of&#xD;
      Seroquel by patients, substitution behavior by prescribers and patients, and health outcomes&#xD;
      of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day equivalent prescribing of Seroquel treatments</measure>
    <time_frame>9 months</time_frame>
    <description>The prescribing of Seroquel over the 9 months following the initial sending of the letters. Prescribing is defined as the total &quot;days supply&quot; of Seroquel attributed to the prescriber, expressed in &quot;30-day equivalents&quot; i.e. divided by 30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day equivalent prescribing of Seroquel treatments</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day equivalent prescribing of Seroquel treatments</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day equivalent prescribing of Seroquel treatments</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5055</enrollment>
  <condition>Economics</condition>
  <condition>Fraud</condition>
  <condition>Delivery of Health Care</condition>
  <condition>Health Expenditures</condition>
  <condition>Centers for Medicare and Medicaid Services (U.S.)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm receives a placebo letter unrelated to Seroquel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Informative Letter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo letter</intervention_name>
    <description>The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Initial Informative letter</intervention_name>
    <description>The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
    <arm_group_label>Informative Letter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Followup Informative Letter</intervention_name>
    <description>The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.</description>
    <arm_group_label>Informative Letter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General care practitioner&#xD;
&#xD;
          -  Outlier with respect to the count of Seroquel prescription drug treatments relative to&#xD;
             peer group of prescribers in 2013 and 2014&#xD;
&#xD;
          -  Outlier with respect to the count of Seroquel 30-day equivalent prescription drug&#xD;
             treatments relative to peer group of prescribers in 2013 and 2014&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Deceased&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Sacarny, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <link>
    <url>https://www.socialscienceregistry.org/trials/729</url>
    <description>American Economic Association Randomized Controlled Trials Registry Entry</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>449</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.socialscienceregistry.org/trials/729</doc_url>
      <doc_comment>Study protocol archived on American Economic Association Social Science Registry page.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>448</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.socialscienceregistry.org/trials/729</doc_url>
      <doc_comment>Pre-specified analysis plan archived on American Economic Association Social Science Registry page.&#xD;
Final version prior to unblinding: Version 2.0 (March 5, 2016)</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

